Buruli ulcer: wound care and rehabilitation

References

• WHO [webpage on the Internet]. Buruli Ulcer (Mycobacterium ulcerans Infection). Fact Sheet N° 199. Geneva: WHO Health Organisation; 2016. Available from: http://www.who.int/mediacentre/factsheets/fs199/en/. Accessed January 30, 2016.
   Google Scholar
• Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol. 2009;7(1):50–60.
   Web of Science ®Google Scholar
• WHO. Treatment of Mycobacterium ulcerans Disease (Buruli Ulcer): Guidance for Health Workers. Geneva: World Health Organization; 2012. (WHO/HTM/NTD/IDM/2012.1).
   Google Scholar
• Bratschi MW, Bolz M, Minyem JC, et al. Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mape Basin of Cameroon. PLoS Negl Trop Dis. 2013;7(6):e2252.
   PubMed Web of Science ®Google Scholar
• Bratschi MW, Ruf MT, Andreoli A, et al. Mycobacterium ulcerans persistence at a village water source of Buruli ulcer patients. PLoS Negl Trop Dis. 2014;8(3):e2756.
   PubMed Web of Science ®Google Scholar
• Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;49(8):3182–3186.
   PubMed Web of Science ®Google Scholar
• Phanzu DM, Suykerbuyk P, Imposo DB, et al. Effect of a control project on clinical profiles and outcomes in buruli ulcer: a before/after study in Bas-Congo, Democratic Republic of Congo. PLoS Negl Trop Dis. 2011;5(12):e1402.
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2010;54(9):3678–3685.
   PubMed Web of Science ®Google Scholar
• Vincent QB, Ardant MF, Adeye A, et al. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. Lancet Glob Health. 2014;2(7):e422–e430.
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Phillips RO, Zhang J, et al. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis. 2014;14:202.
   PubMed Web of Science ®Google Scholar
• Beissner M, Arens N, Wiedemann F, et al. Treatment outcome of patients with Buruli ulcer disease in Togo. PLoS Negl Trop Dis. 2015;9(10):e0004170.
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust. 2007;186(2):58–61.
   PubMed Web of Science ®Google Scholar
• Velding K, Klis SA, Abass KM, Tuah W, Stienstra Y, van der Werf T. Wound care in buruli ulcer disease in Ghana and Benin. Am J Trop Med Hyg. 2014;91(2):313–318.
   PubMed Web of Science ®Google Scholar
• Huygen K, Adjei O, Affolabi D, et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol. 2009;198(2):69–77.
   Web of Science ®Google Scholar
• WHO [webpage on the Internet]. Global Health Observatory Data Repository. Millennium Development Goals 6: Neglected Tropical Diseases [App]. 2014. Available from: http://apps.who.int/neglected_diseases/ntddata/buruli/buruli.html. Accessed January 30, 2016.
   Google Scholar
• WHO [webpage on the Internet]. Buruli Ulcer Endemic Countries. 2016. Available from: http://www.who.int/buruli/country/en/. Accessed January 30, 2016.
   Google Scholar
• Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection. Lancet. 1999;353(9157):986.
   PubMed Web of Science ®Google Scholar
• Merritt RW, Walker ED, Small PL, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis. 2010;4(12):e911.
   PubMed Web of Science ®Google Scholar
• Marion E, Eyangoh S, Yeramian E, et al. Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis. 2010;4(7):e731.
   PubMed Web of Science ®Google Scholar
• Carson C, Lavender CJ, Handasyde KA, et al. Potential wildlife sentinels for monitoring the endemic spread of human buruli ulcer in South-East Australia. PLoS Negl Trop Dis. 2014;8(1):e2668.
   PubMed Web of Science ®Google Scholar
• Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis. 2010;4(8):e791.
   PubMed Web of Science ®Google Scholar
• Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis. 2007;13(11):1653–1660.
   PubMed Web of Science ®Google Scholar
• Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol. 2009;27(3):291–305.
   PubMed Web of Science ®Google Scholar
• Pommelet V, Vincent QB, Ardant MF, et al. Findings in patients from Benin with osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection. Clin Infect Dis. 2014;59(9):1256–1264.
   PubMed Web of Science ®Google Scholar
• Capela C, Sopoh GE, Houezo JG, et al. Clinical epidemiology of Buruli ulcer from Benin (2005-2013): effect of time-delay to diagnosis on clinical forms and severe phenotypes. PLoS Negl Trop Dis. 2015;9(9):e0004005.
   Web of Science ®Google Scholar
• Portaels F, Agular J, Fissette K, et al. Direct detection and identification of Mycobacterium ulcerans in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. J Clin Microbiol. 1997;35(5):1097–1100.
   Web of Science ®Google Scholar
• Phillips R, Horsfield C, Kuijper S, et al. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol. 2005;43(8):3650–3656.
   PubMed Web of Science ®Google Scholar
• Herbinger KH, Adjei O, Awua-Boateng NY, et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis. 2009;48(8):1055–1064.
   PubMed Web of Science ®Google Scholar
• Phillips RO, Sarfo FS, Osei-Sarpong F, et al. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol. 2009;47(4):924–926.
   PubMed Web of Science ®Google Scholar
• Ross BC, Johnson PD, Oppedisano F, et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol. 1997;63(10):4135–4138.
   Web of Science ®Google Scholar
• Stinear T, Ross BC, Davies JK, et al. Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J Clin Microbiol. 1999;37(4):1018–1023.
   PubMed Web of Science ®Google Scholar
• Guimaraes-Peres A, Portaels F, de Rijk P, et al. Comparison of two PCRs for detection of Mycobacterium ulcerans. J Clin Microbiol. 1999;37(1):206–208.
   PubMed Web of Science ®Google Scholar
• Stienstra Y, van der Werf TS, Guarner J, et al. Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic. J Clin Microbiol. 2003;41(2):794–797.
   PubMed Web of Science ®Google Scholar
• Herbinger KH, Beissner M, Huber K, et al. Efficiency of fine-needle aspiration compared with other sampling techniques for laboratory diagnosis of Buruli ulcer disease. J Clin Microbiol. 2010;48(10):3732–3734.
   PubMed Web of Science ®Google Scholar
• Eddyani M, Fraga AG, Schmitt F, et al. Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol. 2009;47(6):1700–1704.
   PubMed Web of Science ®Google Scholar
• Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology. 1985;17(4):594–600.
   PubMed Web of Science ®Google Scholar
• Connor DH, Lunn HF. Mycobacterium ulcerans infection (with comments on pathogenesis). Int J Lepr. 1965;33((3): suppl):698–709.
   Google Scholar
• George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science. 1999;283(5403):854–857.
   PubMed Web of Science ®Google Scholar
• Stinear TP, Mve-Obiang A, Small PL, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A. 2004;101(5):1345–1349.
   PubMed Web of Science ®Google Scholar
• Mve-Obiang A, Lee RE, Portaels F, Small PL. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun. 2003;71(2):774–783.
   Web of Science ®Google Scholar
• Snyder DS, Small PL. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog. 2003;34(2):91–101.
   PubMed Web of Science ®Google Scholar
• Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501–1512.
   PubMed Web of Science ®Google Scholar
• Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol. 2009;182(4):2194–2202.
   PubMed Web of Science ®Google Scholar
• Coutanceau E, Decalf J, Martino A, et al. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med. 2007;204(6):1395–1403.
   PubMed Web of Science ®Google Scholar
• Boulkroun S, Guenin-Mace L, Thoulouze MI, et al. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol. 2010;184(3):1436–1444.
   PubMed Web of Science ®Google Scholar
• Guenin-Mace L, Carrette F, Asperti-Boursin F, et al. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A. 2011;108(31):12833–12838.
   PubMed Web of Science ®Google Scholar
• Hall B, Simmonds R. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochem Soc Trans. 2014;42(1):177–183.
   PubMed Web of Science ®Google Scholar
• Ogbechi J, Ruf MT, Hall BS, et al. Mycolactone-dependent depletion of endothelial cell thrombomodulin is strongly associated with fibrin deposition in Buruli ulcer lesions. PLoS Pathog. 2015;11(7):e1005011.
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17–29.
   PubMed Web of Science ®Google Scholar
• Havel A, Pattyn SR. Activity of rifampicin on Mycobacterium ulcerans. Ann Soc Belg Med Trop. 1975;55(2):105–108.
   Google Scholar
• Thangaraj HS, Adjei O, Allen BW, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother. 2000;45(2):231–233.
   PubMed Web of Science ®Google Scholar
• Portaels F, Traore H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother. 1998;42(8):2070–2073.
   PubMed Web of Science ®Google Scholar
• Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2001;45(11):3109–3112.
   PubMed Web of Science ®Google Scholar
• Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2000;44(9):2367–2372.
   PubMed Web of Science ®Google Scholar
• Stanford JL, Phillips I. Rifampicin in experimental Mycobacterium ulcerans infection. J Med Microbiol. 1972;5(1):39–45.
   Web of Science ®Google Scholar
• Marsollier L, Honore N, Legras P, et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother. 2003;47(4):1228–1232.
   PubMed Web of Science ®Google Scholar
• Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51(11):4029–4035.
   PubMed Web of Science ®Google Scholar
• Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet. 2010;375(9715):664–672.
   PubMed Web of Science ®Google Scholar
• Phillips RO, Sarfo FS, Abass MK, et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2014;58(4):2488.
   Web of Science ®Google Scholar
• O’Brien DP, Comte E, Ford N, Christinet V, du Cros P. Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? AIDS. 2013;27(14):2177–2179.
   Web of Science ®Google Scholar
• Ruf MT, Chauty A, Adeye A, et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis. 2011;5(8):e1252.
   PubMed Web of Science ®Google Scholar
• Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis. 2012;54(4):519–526.
   PubMed Web of Science ®Google Scholar
• Wanda F, Nkemenang P, Ehounou G, et al. Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection. BMC Infect Dis. 2014;14:423.
   Web of Science ®Google Scholar
• O’Brien DP, Robson ME, Callan PP, McDonald AH. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust. 2009;191(10):564–566.
   PubMed Web of Science ®Google Scholar
• Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989;24(3):281–293.
   Web of Science ®Google Scholar
• Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119–126.
   PubMed Web of Science ®Google Scholar
• Klis S, Stienstra Y, Phillips RO, Abass KM, Tuah W, van der Werf TS. Long term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of participants in the BURULICO drug trial. PLoS Negl Trop Dis. 2014;8(3):e2739.
   PubMed Web of Science ®Google Scholar
• Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249(2–3):91–96.
   PubMed Web of Science ®Google Scholar
• WHO [webpage on the Internet]. Wound Management. 2015. Available from: http://www.who.int/buruli/information/publications/BU-5POD-interventions-2.pdf?ua=1. Assessed October 7, 2015.
   Google Scholar
• Lee JC, Kandula S, Sherber NS. Beyond wet-to-dry: a rational approach to treating chronic wounds. Eplasty. 2009;9:e14.
   Google Scholar
• WHO, Macdonald JM, Geyer MJ. Wound and Lymphoedema Management. Geneva: World Health Organization; 2010.
   Google Scholar
• Lehman L, Simonet V, Saunderson P, Agbenorku P. Buruli Ulcer: Prevention of Disability (POD). Geneva: World Health Organization; 2006.
   Google Scholar
• Welch JS, Bunting TG. The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. J Trauma. 1993;35(3):491–492.
   Google Scholar
• Thomas GW, Rael LT, Bar-Or R, et al. Mechanisms of delayed wound healing by commonly used antiseptics. J Trauma. 2009;66(1):82–90.
   Google Scholar
• Wilson JR, Mills JG, Prather ID, Dimitrijevich SD. A toxicity index of skin and wound cleansers used on in vitro fibroblasts and keratinocytes. Adv Skin Wound Care. 2005;18(7):373–378.
   PubMedGoogle Scholar
• Sarabahi S. Recent advances in topical wound care. Indian J Plast Surg. 2012;45(2):379–387.
   PubMedGoogle Scholar
• O’Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess. 2000;4(21):1–237.
   Google Scholar
• Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds. Health Technol Assess. 1999;3(17 pt 2):1–35.
   Google Scholar
• Amoakoh HB, Aikins M. Household cost of out-patient treatment of Buruli ulcer in Ghana: a case study of Obom in Ga South Municipality. BMC Health Serv Res. 2013;13:507.
   PubMed Web of Science ®Google Scholar
• Brown A, Yorke M. Drawtex: breaking the vicious circle of cellular and molecular imbalances. Br J Community Nurs. 2013;(suppl): S42, S44, S46–S44.
   Google Scholar
• Davies P, Rippon M. Comparison of Foam and Hydrocolloid Dressings in the Management of Wounds: A Review of the Published Literature. 2010. Available from: http://www.worldwidewounds.com/2010/July/DaviesRippon/DaviesRippon.html. Accessed January 30, 2016.
   Google Scholar
• Martini L, Reali UM, Borgognoni L, Brandani P, Andriessen A. Comparison of two dressings in the management of partial-thickness donor sites. J Wound Care. 1999;8(9):457–460.
   Google Scholar
• Chang KW, Alsagoff S, Ong KT, Sim PH. Pressure ulcers – randomised controlled trial comparing hydrocolloid and saline gauze dressings. Med J Malaysia. 1998;53(4):428–431.
   Google Scholar
• Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M. Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother. 2004;48(8):2866–2870.
   Web of Science ®Google Scholar
• Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, Kolk AH. In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother. 2004;48(8):3130–3132.
   Web of Science ®Google Scholar
• Adjei O, Evans MR, Asiedu A. Phenytoin in the treatment of Buruli ulcer. Trans R Soc Trop Med Hyg. 1998;92(1):108–109.
   Web of Science ®Google Scholar
• Reid IS. Mycobacterium ulcerans infection: a report of 13 cases at the Port Moresby General Hospital, Papua. Med J Aust. 1967;1(9):427–431.
   PubMedGoogle Scholar
• Glynn PJ. The use of surgery and local temperature elevation in Mycobacterium ulcerans infection. Aust N Z J Surg. 1972;41(4):312–317.
   Google Scholar
• Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg. 1974;23(5):924–929.
   PubMed Web of Science ®Google Scholar
• Krieg RE, Wolcott JH, Confer A. Treatment of Mycobacterium ulcerans infection by hyperbaric oxygenation. Aviat Space Environ Med. 1975;46(10):1241–1245.
   Google Scholar
• Krieg RE, Wolcott JH, Meyers WM. Mycobacterium ulcerans infection: treatment with rifampin, hyperbaric oxygenation, and heat. Aviat Space Environ Med. 1979;50(9):888–892.
   Google Scholar
• Landier J, Boisier P, Fotso Piam F, et al. Adequate wound care and use of bed nets as protective factors against Buruli ulcer: results from a case control study in Cameroon. PLoS Negl Trop Dis. 2011;5(11):e1392.
   PubMed Web of Science ®Google Scholar
• Yeboah-Manu D, Kpeli GS, Ruf MT, et al. Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis. 2013;7(5):e2191.
   PubMed Web of Science ®Google Scholar
• Barogui YT, Klis S, Bankole HS, et al. Towards rational use of antibiotics for suspected secondary infections in buruli ulcer patients. PLoS Negl Trop Dis. 2013;7(1):e2010.
   PubMed Web of Science ®Google Scholar
• Amissah NA, Chlebowicz MA, Ablordey A, et al. Molecular characterization of Staphylococcus aureus isolates transmitted between patients with Buruli ulcer. PLoS Negl Trop Dis. 2015;9(9):e0004049.
   PubMed Web of Science ®Google Scholar
• Amissah NA, Glasner C, Ablordey A, et al. Genetic diversity of Staphylococcus aureus in Buruli ulcer. PLoS Negl Trop Dis. 2015;9(2):e0003421.
   PubMed Web of Science ®Google Scholar
• Geroult S, Phillips RO, Demangel C. Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings. J Wound Care. 2014;23(8):417–424.
   Web of Science ®Google Scholar
• de Jong A, Baartmans M, Bremer M, et al. Reliability, validity and clinical utility of three types of pain behavioural observation scales for young children with burns aged 0-5 years. Pain. 2010;150(3):561–567.
   Web of Science ®Google Scholar
• Alferink M, de Zeeuw J, Sopoh G, et al. Pain associated with wound care treatment among Buruli ulcer patients from Ghana and Benin. PLoS One. 2015;10(6):e0119926.
   Web of Science ®Google Scholar
• de Zeeuw J, Alferink M, Barogui YT, et al. Assessment and treatment of pain during treatment of Buruli ulcer. PLoS Negl Trop Dis. 2015;9(9):e0004076.
   PubMed Web of Science ®Google Scholar
• Agbenorku P, Donwi IK, Kuadzi P, Saunderson P. Buruli ulcer: treatment challenges at three centres in Ghana. Re Dai Yi Xue Za Zhi. 2012;2012:371915.
   Google Scholar
• Agbenorku P, Agbenorku M, Amankwa A, Tuuli L, Saunderson P. Factors enhancing the control of Buruli ulcer in the Bomfa communities, Ghana. Trans R Soc Trop Med Hyg. 2011;105(8):459–465.
   Web of Science ®Google Scholar
• Agbenorku P. Multicenter study of buruli ulcer disabilities in the head and neck region. Plast Surg Int. 2011;2011:647418.
   Google Scholar
• Agbenorku P, Edusei A, Agbenorku M, et al. Buruli-ulcer induced disability in Ghana: a study at Apromase in the Ashanti Region. Plast Surg Int. 2012;2012:752749.
   Google Scholar
• Agbenorku P, Agbenorku M, Saunderson P, Lehman L. The benefits of a combination of surgery and chemotherapy in the management of Buruli ulcer patients. J Sci Technol. 2006;26(2):6–10.
   Google Scholar
• Stienstra Y, van Roest MH, van Wezel MJ, et al. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health. 2005;10(12):1251–1257.
   PubMed Web of Science ®Google Scholar
• Barogui Y, Johnson RC, van der Werf TS, et al. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg. 2009;81(1):82–87.
   PubMed Web of Science ®Google Scholar
• van der Werf TS, Stienstra Y, Johnson RC, et al. Mycobacterium ulcerans disease. Bull World Health Organ. 2005;83(10):785–791.
   PubMed Web of Science ®Google Scholar
• Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg. 1998;59(6):1015–1022.
   PubMed Web of Science ®Google Scholar
• Schunk M, Thompson W, Klutse E, et al. Outcome of patients with buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. Am J Trop Med Hyg. 2009;81(1):75–81.
   Web of Science ®Google Scholar
• Stienstra Y, Dijkstra PU, Guedenon A, et al. Development of a questionnaire assessing Buruli ulcer-induced functional limitation. Am J Trop Med Hyg. 2004;70(3):318–322.
   Web of Science ®Google Scholar
• Stienstra Y, Dijkstra PU, Van Wezel MJ, et al. Reliability and validity of the Buruli ulcer functional limitation score questionnaire. Am J Trop Med Hyg. 2005;72(4):449–452.
   Web of Science ®Google Scholar
• World Health Organisation (WHO) [webpage on the Internet]. Concepts of Prevention of Disability and Rehabilitation. 2015. Available from: http://www.who.int/buruli/information/publications/pod/en/. Assessed October 7, 2015.
   Google Scholar
• WHO [webpage on the Internet]. WHO Publications on Buruli Ulcer Available from: http://www.who.int/buruli/information/publications/en/. Accessed January 30, 2016.
   Google Scholar
• WHO [webpage on the Internet]. Simonet V, editor. Prevention of Disability in Buruli Ulcer: Basic Rehabilitation. A Practical Field Guide. Geneva: World Health Organization; 2008. Available from: http://whqlibdoc.who.int/hq/2008/WHO_HTM_NTD_IDM_GBUI_2008.1_eng.pdf. Accessed January 30, 2016.
   Google Scholar
• Ellen DE, Stienstra Y, Teelken MA, Dijkstra PU, van der Graaf WT, van der Werf TS. Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score. Trop Med Int Health. 2003;8(1):90–96.
   Web of Science ®Google Scholar
• de Zeeuw J, Omansen TF, Douwstra M, et al. Persisting social participation restrictions among former buruli ulcer patients in Ghana and Benin. PLoS Negl Trop Dis. 2014;8(11):e3303.
   PubMed Web of Science ®Google Scholar
• Stienstra Y, van der Graaf WT, Asamoa K, van der Werf TS. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg. 2002;67(2):207–213.
   PubMed Web of Science ®Google Scholar
• Kpadonou TG, Alagnide E, Azanmasso H, et al. Psychosocioprofessional and familial becoming of formers Buruli ulcer patients in Benin. Ann Phys Rehabil Med. 2013;56(7–8):515–526.
   Google Scholar
• de Zeeuw J, Douwstra M, Omansen TF, et al. Psychometric properties of the participation scale among former buruli ulcer patients in Ghana and Benin. PLoS Negl Trop Dis. 2014;8(11):e3254.
   PubMed Web of Science ®Google Scholar
• Renzaho AM, Woods PV, Ackumey MM, Harvey SK, Kotin J. Community-based study on knowledge, attitude and practice on the mode of transmission, prevention and treatment of the Buruli ulcer in Ga West District, Ghana. Trop Med Int Health. 2007;12(3):445–458.
   PubMed Web of Science ®Google Scholar
• Adamba C, Owusu AY. Burden of Buruli ulcer: how affected households in a Ghanaian district cope. Afr Study Monogr. 2011;32(1):1–23.
   Google Scholar
• World Health Organization (WHO). International Classification of Functioning, Disability and Health: ICF. Geneva: World Health Organization; 2001.
   Google Scholar
• Hamzat TK, Boakye-Afram B. Health-related quality of life among persons living with Buruli ulcer in Amasaman community, Ga West District Accra, Ghana. Int J Health Sci. 2011;5(1):29–38.
   Google Scholar
• Klis S, Ranchor A, Phillips RO, et al. Good quality of life in former Buruli ulcer patients with small lesions: long-term follow-up of the BURULICO trial. PLoS Negl Trop Dis. 2014;8(7):e2964.
   Web of Science ®Google Scholar